PFS-话题@MedSci

#PFS#

70篇内容 | 2855人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1448673, encodeId=8df714486e3b0, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=傻傻分不清 || ORR、DCR、PFS、OS，评价肿瘤结局的客观指标是什么？, objectType=article, longId=206064, objectId=3a042060646e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a042060646e, replyNumber=0, likeNumber=89, createdTime=2021-01-24, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a042060646e, moduleTitle=傻傻分不清 || ORR、DCR、PFS、OS，评价肿瘤结局的客观指标是什么？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a042060646e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448672, encodeId=065e14486e2a4, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS, objectType=article, longId=206058, objectId=87ad20605893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87ad20605893, replyNumber=0, likeNumber=75, createdTime=2021-01-24, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87ad20605893, moduleTitle=BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87ad20605893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448671, encodeId=972c14486e1db, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, objectType=article, longId=205930, objectId=92a920593034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92a920593034, replyNumber=0, likeNumber=101, createdTime=2021-01-21, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92a920593034, moduleTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92a920593034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448670, encodeId=102d14486e055, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=妇瘤探案 | 82岁/BRCAwt/心梗后，奥拉帕利维持治疗对高龄复发性卵巢癌患者有显效，PFS超22个月！, objectType=article, longId=204483, objectId=c6282044830a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6282044830a, replyNumber=0, likeNumber=102, createdTime=2020-12-15, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6282044830a, moduleTitle=妇瘤探案 | 82岁/BRCAwt/心梗后，奥拉帕利维持治疗对高龄复发性卵巢癌患者有显效，PFS超22个月！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6282044830a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448669, encodeId=31b41448669df, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著, objectType=article, longId=201382, objectId=2172201382b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2172201382b6, replyNumber=0, likeNumber=79, createdTime=2020-10-01, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2172201382b6, moduleTitle=君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2172201382b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448668, encodeId=971f144866855, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到, objectType=article, longId=198983, objectId=4d33198983b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d33198983b2, replyNumber=0, likeNumber=88, createdTime=2020-08-09, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d33198983b2, moduleTitle=罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d33198983b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448667, encodeId=cf4d144866e13, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点, objectType=article, longId=197187, objectId=f91619e187c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f91619e187c8, replyNumber=0, likeNumber=67, createdTime=2020-07-09, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f91619e187c8, moduleTitle=抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f91619e187c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448666, encodeId=da0214486663f, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, objectType=article, longId=193345, objectId=a58619334571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a58619334571, replyNumber=0, likeNumber=42, createdTime=2020-05-03, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a58619334571, moduleTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a58619334571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448665, encodeId=11ff144866535, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=肿瘤中的中位PFS：不能过度迷信，这里也有陷阱, objectType=article, longId=190136, objectId=f2b719013696, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2b719013696, replyNumber=0, likeNumber=93, createdTime=2020-03-18, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2b719013696, moduleTitle=肿瘤中的中位PFS：不能过度迷信，这里也有陷阱, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2b719013696)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448664, encodeId=5ce3144866494, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=DARZALEX（Daratumumab）方案显著增加复发难治多发性骨髓瘤患者的PFS, objectType=article, longId=184567, objectId=14fb18456e61, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14fb18456e61, replyNumber=0, likeNumber=85, createdTime=2019-12-13, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14fb18456e61, moduleTitle=DARZALEX（Daratumumab）方案显著增加复发难治多发性骨髓瘤患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14fb18456e61)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448663, encodeId=dfac14486630e, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ALK阳性NSCLC的治疗如何权衡PFS和OS？, objectType=article, longId=184371, objectId=c0ab1843e149, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0ab1843e149, replyNumber=0, likeNumber=70, createdTime=2019-12-08, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0ab1843e149, moduleTitle=ALK阳性NSCLC的治疗如何权衡PFS和OS？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0ab1843e149)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448662, encodeId=2733144866280, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**, objectType=article, longId=183976, objectId=367f1839e6b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=367f1839e6b1, replyNumber=0, likeNumber=0, createdTime=2019-12-04, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367f1839e6b1, moduleTitle=长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=367f1839e6b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448661, encodeId=6de2144866151, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS, objectType=article, longId=183104, objectId=0beb18310413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0beb18310413, replyNumber=0, likeNumber=85, createdTime=2019-11-19, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0beb18310413, moduleTitle=JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0beb18310413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448660, encodeId=cce61448660dc, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=2019 ESMO|内分泌治疗是激素受体阳性乳腺癌重要的治疗手段，Abemaciclib显著延长HR+/HER2-mBC患者PFS, objectType=article, longId=181298, objectId=eae9181298b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae9181298b0, replyNumber=0, likeNumber=63, createdTime=2019-10-17, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae9181298b0, moduleTitle=2019 ESMO|内分泌治疗是激素受体阳性乳腺癌重要的治疗手段，Abemaciclib显著延长HR+/HER2-mBC患者PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae9181298b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448659, encodeId=d3921448659d0, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=PFS超63个月！还原这例三阳性乳腺癌患者的诊疗过程, objectType=article, longId=181038, objectId=eaaf181038b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eaaf181038b9, replyNumber=0, likeNumber=79, createdTime=2019-10-14, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eaaf181038b9, moduleTitle=PFS超63个月！还原这例三阳性乳腺癌患者的诊疗过程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eaaf181038b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448658, encodeId=d4c814486589f, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ESMO 2019∣帕博利珠单抗联合化疗显著延长PFS2，免疫治疗越早使用越好, objectType=article, longId=180793, objectId=fd6a180e93a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd6a180e93a8, replyNumber=0, likeNumber=87, createdTime=2019-10-11, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd6a180e93a8, moduleTitle=ESMO 2019∣帕博利珠单抗联合化疗显著延长PFS2，免疫治疗越早使用越好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd6a180e93a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448657, encodeId=810e144865e27, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=Lancet Oncol：阿昔替尼联合帕博利珠单抗治疗晚期肉瘤，PFS率远超历史, objectType=article, longId=166056, objectId=9bff16605624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bff16605624, replyNumber=0, likeNumber=87, createdTime=2019-05-16, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bff16605624, moduleTitle=Lancet Oncol：阿昔替尼联合帕博利珠单抗治疗晚期肉瘤，PFS率远超历史, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bff16605624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448656, encodeId=1f761448656b1, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=darolutamide联合雄激素剥夺疗法在非转移性去势抵抗性前列腺癌中显著延长了PFS, objectType=article, longId=160341, objectId=61af160341ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61af160341ee, replyNumber=0, likeNumber=61, createdTime=2019-02-19, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61af160341ee, moduleTitle=darolutamide联合雄激素剥夺疗法在非转移性去势抵抗性前列腺癌中显著延长了PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61af160341ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448655, encodeId=8bc714486552f, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=青年群体的智慧，探索ALK+一线34.8个月PFS耐药后的治疗, objectType=article, longId=150114, objectId=da111501140c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da111501140c, replyNumber=0, likeNumber=68, createdTime=2018-10-02, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da111501140c, moduleTitle=青年群体的智慧，探索ALK+一线34.8个月PFS耐药后的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da111501140c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448654, encodeId=bff41448654e7, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=2018年WCLC：Durvalumab有助于维持无法切除的III期非小细胞肺癌的PFS, objectType=article, longId=149831, objectId=c67914983121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c67914983121, replyNumber=0, likeNumber=81, createdTime=2018-09-29, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c67914983121, moduleTitle=2018年WCLC：Durvalumab有助于维持无法切除的III期非小细胞肺癌的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c67914983121)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PFS

2020-05-29

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

傻傻分不清 || ORR、DCR、PFS、OS，评价肿瘤结局的客观指标是什么？

2021-01-24

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

BRCA1/2突变铂敏感型复发性卵巢癌：奥拉帕利较非铂化疗能有效改善PFS

2021-01-24

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）

2021-01-21

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

妇瘤探案 | 82岁/BRCAwt/心梗后，奥拉帕利维持治疗对高龄复发性卵巢癌患者有显效，PFS超22个月！

2020-12-15

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著

2020-10-01

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

罗氏Tecentriq联合紫杉醇用于三阴性乳腺癌研究主要终点PFS未能达到

2020-08-09

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点

2020-07-09

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）

2020-05-03

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

肿瘤中的中位PFS：不能过度迷信，这里也有陷阱

2020-03-18

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

DARZALEX（Daratumumab）方案显著增加复发难治多发性骨髓瘤患者的PFS

2019-12-13

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ALK阳性NSCLC的治疗如何权衡PFS和OS？

2019-12-08

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**

2019-12-04

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS

2019-11-19

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

2019 ESMO|内分泌治疗是激素受体阳性乳腺癌重要的治疗手段，Abemaciclib显著延长HR+/HER2-mBC患者PFS

2019-10-17

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

PFS超63个月！还原这例三阳性乳腺癌患者的诊疗过程

2019-10-14

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ESMO 2019∣帕博利珠单抗联合化疗显著延长PFS2，免疫治疗越早使用越好

2019-10-11

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

Lancet Oncol：阿昔替尼联合帕博利珠单抗治疗晚期肉瘤，PFS率远超历史

2019-05-16

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

darolutamide联合雄激素剥夺疗法在非转移性去势抵抗性前列腺癌中显著延长了PFS

2019-02-19

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

青年群体的智慧，探索ALK+一线34.8个月PFS耐药后的治疗

2018-10-02

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

2018年WCLC：Durvalumab有助于维持无法切除的III期非小细胞肺癌的PFS

2018-09-29

科室
- - 订阅+
  - 更多科室
工具
服务